Name | Number of supported studies | Average coverage | |
---|---|---|---|
classical monocyte | 21 studies | 37% ± 16% | |
macrophage | 19 studies | 24% ± 9% | |
monocyte | 17 studies | 25% ± 9% | |
natural killer cell | 16 studies | 23% ± 5% | |
CD16-positive, CD56-dim natural killer cell, human | 13 studies | 31% ± 11% | |
myeloid cell | 11 studies | 33% ± 17% | |
CD16-negative, CD56-bright natural killer cell, human | 9 studies | 32% ± 13% | |
microglial cell | 9 studies | 34% ± 13% | |
neutrophil | 5 studies | 25% ± 12% | |
non-classical monocyte | 5 studies | 20% ± 3% | |
dendritic cell | 5 studies | 24% ± 4% | |
conventional dendritic cell | 4 studies | 28% ± 12% | |
mature NK T cell | 4 studies | 20% ± 7% | |
mononuclear phagocyte | 4 studies | 17% ± 2% | |
CD8-positive, alpha-beta T cell | 3 studies | 18% ± 1% | |
alveolar macrophage | 3 studies | 27% ± 7% | |
mast cell | 3 studies | 21% ± 4% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 5 studies | 27% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 3811.33 | 578 / 578 | 88% | 15.56 | 1021 / 1155 |
breast | 88% | 846.84 | 403 / 459 | 93% | 15.08 | 1035 / 1118 |
bladder | 95% | 798.24 | 20 / 21 | 56% | 6.35 | 282 / 504 |
brain | 58% | 407.91 | 1535 / 2642 | 91% | 12.86 | 639 / 705 |
thymus | 66% | 407.68 | 433 / 653 | 80% | 7.99 | 485 / 605 |
intestine | 90% | 808.48 | 866 / 966 | 55% | 5.84 | 288 / 527 |
kidney | 49% | 410.69 | 44 / 89 | 88% | 13.13 | 793 / 901 |
uterus | 70% | 438.09 | 119 / 170 | 61% | 5.82 | 280 / 459 |
esophagus | 69% | 577.29 | 996 / 1445 | 61% | 4.77 | 112 / 183 |
adrenal gland | 94% | 1095.98 | 243 / 258 | 35% | 2.03 | 80 / 230 |
pancreas | 33% | 206.68 | 108 / 328 | 90% | 15.20 | 161 / 178 |
stomach | 58% | 450.70 | 209 / 359 | 64% | 6.09 | 182 / 286 |
prostate | 67% | 427.00 | 164 / 245 | 47% | 2.53 | 235 / 502 |
skin | 31% | 154.27 | 565 / 1809 | 78% | 9.56 | 368 / 472 |
liver | 51% | 317.23 | 115 / 226 | 51% | 5.63 | 209 / 406 |
ovary | 43% | 244.83 | 77 / 180 | 59% | 5.23 | 255 / 430 |
lymph node | 0% | 0 | 0 / 0 | 100% | 23.93 | 29 / 29 |
spleen | 100% | 7047.05 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 99% | 2102.24 | 1194 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 97% | 19547.65 | 900 / 929 | 0% | 0 | 0 / 0 |
blood vessel | 81% | 870.09 | 1076 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 76% | 12.37 | 34 / 45 |
heart | 70% | 518.35 | 602 / 861 | 0% | 0 | 0 / 0 |
muscle | 18% | 85.43 | 144 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 10% | 0.45 | 8 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0032355 | Biological process | response to estradiol |
GO_0098742 | Biological process | cell-cell adhesion via plasma-membrane adhesion molecules |
GO_0033627 | Biological process | cell adhesion mediated by integrin |
GO_0002931 | Biological process | response to ischemia |
GO_0001774 | Biological process | microglial cell activation |
GO_0140459 | Biological process | response to Gram-positive bacterium |
GO_0150062 | Biological process | complement-mediated synapse pruning |
GO_0006898 | Biological process | receptor-mediated endocytosis |
GO_0045087 | Biological process | innate immune response |
GO_0007160 | Biological process | cell-matrix adhesion |
GO_0030900 | Biological process | forebrain development |
GO_0150064 | Biological process | vertebrate eye-specific patterning |
GO_0007155 | Biological process | cell adhesion |
GO_0034113 | Biological process | heterotypic cell-cell adhesion |
GO_0006911 | Biological process | phagocytosis, engulfment |
GO_0043315 | Biological process | positive regulation of neutrophil degranulation |
GO_0097242 | Biological process | amyloid-beta clearance |
GO_0045963 | Biological process | negative regulation of dopamine metabolic process |
GO_0007229 | Biological process | integrin-mediated signaling pathway |
GO_0090314 | Biological process | positive regulation of protein targeting to membrane |
GO_1904643 | Biological process | response to curcumin |
GO_0032930 | Biological process | positive regulation of superoxide anion generation |
GO_0009612 | Biological process | response to mechanical stimulus |
GO_1904151 | Biological process | positive regulation of microglial cell mediated cytotoxicity |
GO_0098609 | Biological process | cell-cell adhesion |
GO_0010668 | Biological process | ectodermal cell differentiation |
GO_2000363 | Biological process | positive regulation of prostaglandin-E synthase activity |
GO_0002430 | Biological process | complement receptor mediated signaling pathway |
GO_0005615 | Cellular component | extracellular space |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0035579 | Cellular component | specific granule membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0008305 | Cellular component | integrin complex |
GO_0070062 | Cellular component | extracellular exosome |
GO_0009986 | Cellular component | cell surface |
GO_0044853 | Cellular component | plasma membrane raft |
GO_0070821 | Cellular component | tertiary granule membrane |
GO_0034688 | Cellular component | integrin alphaM-beta2 complex |
GO_0031072 | Molecular function | heat shock protein binding |
GO_0038024 | Molecular function | cargo receptor activity |
GO_0001540 | Molecular function | amyloid-beta binding |
GO_0005178 | Molecular function | integrin binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0001851 | Molecular function | complement component C3b binding |
GO_0005515 | Molecular function | protein binding |
Gene name | ITGAM |
Protein name | Integrin subunit alpha M Integrin alpha-M (CD11 antigen-like family member B) (CR-3 alpha chain) (Cell surface glycoprotein MAC-1 subunit alpha) (Leukocyte adhesion receptor MO1) (Neutrophil adherence receptor) (CD antigen CD11b) Integrin alpha-M |
Synonyms | CD11B CR3A |
Description | FUNCTION: Integrin ITGAM/ITGB2 is implicated in various adhesive interactions of monocytes, macrophages and granulocytes as well as in mediating the uptake of complement-coated particles and pathogens . It is identical with CR-3, the receptor for the iC3b fragment of the third complement component. It probably recognizes the R-G-D peptide in C3b. Integrin ITGAM/ITGB2 is also a receptor for fibrinogen, factor X and ICAM1. It recognizes P1 and P2 peptides of fibrinogen gamma chain. Regulates neutrophil migration . In association with beta subunit ITGB2/CD18, required for CD177-PRTN3-mediated activation of TNF primed neutrophils . May regulate phagocytosis-induced apoptosis in extravasated neutrophils (By similarity). May play a role in mast cell development (By similarity). Required with TYROBP/DAP12 in microglia to control production of microglial superoxide ions which promote the neuronal apoptosis that occurs during brain development (By similarity). . |
Accessions | I3NI33 ENST00000565142.1 H3BMV4 A0A3T1DF60 A0A3T1DFB0 ENST00000567031.1 P11215 ENST00000544665.9 [P11215-1] ENST00000648685.1 [P11215-2] |